← Back to headlines
HSBC Downgrades AstraZeneca Following Key Trial Failure
HSBC has downgraded AstraZeneca after the pharmaceutical company reported the failure of a key clinical trial, impacting its stock outlook.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.